Another Approval for Personalized Cellular CAR T Therapy
The FDA has given another approval to Novartis for chimeric antigen receptor (CAR) T-cell therapy KYMRIAH, a personalized cell therapy product, the development of which was originated at University of Pennsylvania. Originally approved for children a...
Source: Medgadget - Category: Medical Devices Authors: Editors Tags: Oncology Source Type: blogs